Table 3.
Radiation improved overall survival.
| Stage | Radiation | No Radiation | Radiation Difference | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| N | % pt | MS (95% CI) | N | %pt | MS ( 95% CI) | *P value | MS Gain (months) | |||
| I | 7473 | 14% | 18 (18, 19) | 9732 | 18% | 12 (11, 12) | <0.0001 | 6 | ||
| II | 1931 | 18% | 15 (14, 15) | 1484 | 14% | 7 (7, 9) | <0.0001 | 8 | ||
| III | 29795 | 40% | 11 (n/a, n/a) | 31935 | 43% | 4 (n/a, n/a) | <0.0001 | 7 | ||
| IV | 50325 | 43% | 5 (n/a, n/a) | 62865 | 54% | 3 (n/a, n/a) | <0.0001 | 2 | ||
| Unknown | 4109 | 13% | 12 (n/a, n/a) | 25006 | 78% | 5 (4, 5) | <0.0001 | 7 | ||
| Total | 93633 | 32% | 8 (n/a, n/a) | 131022 | 45% | 4 (n/a, n/a) | <0.0001 | 4 | ||
Note: MS=median survival in months, CI = confidence interval, pt = patient, na= an interval that was too narrow to be computable.
*The P-values are for the overall difference between the time periods for each stage.
Among NSCLC patients receiving radiotherapy without surgery, radiotherapy improved median survival across all stages.